Chemotherapy for metastatic castrate-sensitive prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Emerging evidence supports combining docetaxel chemotherapy with androgen deprivation therapy (ADT) for metastatic castrate-sensitive prostate cancer (mCSPC).
• Prostate cancer remains a significant health concern, necessitating effective treatment strategies for advanced stages.

Purpose of the Study:

• To review and synthesize findings from pivotal Phase III clinical trials evaluating docetaxel plus ADT in mCSPC.
• To assess the efficacy and survival benefits of this combination therapy.

Main Methods:

• Systematic review of three key randomized Phase III trials: GETUG15, CHAARTED, and STAMPEDE.
• Analysis of progression-free survival (PFS) and overall survival (OS) data from included trials.

Main Results:

• All three trials demonstrated a significant benefit in progression-free survival with the addition of docetaxel to ADT.
• Two trials (CHAARTED and STAMPEDE) showed a clinically meaningful improvement in overall survival.
• The GETUG15 trial did not demonstrate a major overall survival benefit, highlighting trial-specific nuances.

Conclusions:

• Docetaxel in combination with ADT is a valuable treatment option for eligible men with newly diagnosed metastatic prostate cancer.
• This combination therapy offers significant survival advantages for a majority of mCSPC patients.
• Treatment decisions should consider individual patient fitness and trial-specific outcomes.